• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.

作者信息

Guo Junyi, Huang Zheng, Lin Li, Lv Jiagao

机构信息

Division of Cardiology Department of Internal Medicine Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan China.

Division of Gastroenterology Department of Internal Medicine Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan China.

出版信息

J Am Heart Assoc. 2020 Apr 7;9(7):e016219. doi: 10.1161/JAHA.120.016219. Epub 2020 Apr 1.

DOI:10.1161/JAHA.120.016219
PMID:32233755
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7428639/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38de/7428639/5a49b5c51393/JAH3-9-e016219-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38de/7428639/5a49b5c51393/JAH3-9-e016219-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38de/7428639/5a49b5c51393/JAH3-9-e016219-g001.jpg

相似文献

1
Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.2019冠状病毒病（COVID-19）与心血管疾病：关于血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂对严重急性呼吸综合征冠状病毒2感染的发病和严重程度潜在影响的观点
J Am Heart Assoc. 2020 Apr 7;9(7):e016219. doi: 10.1161/JAHA.120.016219. Epub 2020 Apr 1.
2
[Effects of angiotensin converting enzyme inhibitor/angiotensin receptor blocker on clinical characteristics of coronavirus disease 2019 patients with hypertension].血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂对2019冠状病毒病合并高血压患者临床特征的影响
Zhonghua Nei Ke Za Zhi. 2020 Sep 1;59(9):689-694. doi: 10.3760/cma.j.cn112138-20200229-00155.
3
Update Alert 3: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.更新警报3：成人中血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂对严重急性呼吸综合征冠状病毒2感染的风险及影响
Ann Intern Med. 2020 Oct 6;173(7):130-131. doi: 10.7326/L20-1068. Epub 2020 Aug 26.
4
Response to "COVID-19 and ACEI/ARB: Not Associated?".对《COVID-19与ACEI/ARB：无关联？》的回应
Am J Hypertens. 2020 Aug 4;33(8):789-790. doi: 10.1093/ajh/hpaa077.
5
COVID-19 and ACEI/ARB: Not Associated?新冠病毒肺炎与血管紧张素转换酶抑制剂/血管紧张素Ⅱ受体阻滞剂：没有关联？
Am J Hypertens. 2020 Aug 4;33(8):788. doi: 10.1093/ajh/hpaa076.
6
Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19.假说：血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂可能会增加 COVID-19 重症风险。
J Travel Med. 2020 May 18;27(3). doi: 10.1093/jtm/taaa041.
7
Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers.血管紧张素转换酶2与炎症消退：支持继续使用处方血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂
Mayo Clin Proc. 2020 Jul;95(7):1552-1553. doi: 10.1016/j.mayocp.2020.05.001. Epub 2020 May 21.
8
Update Alert: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.最新警报：成人中血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂对严重急性呼吸综合征冠状病毒2感染的风险及影响
Ann Intern Med. 2020 Aug 4;173(3):W66. doi: 10.7326/L20-0887. Epub 2020 Jun 25.
9
Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19.冠状病毒与 ACE2、血管紧张素 II 和 RAS 抑制剂的相互作用——来自现有证据的教训和对 COVID-19 的深入了解。
Hypertens Res. 2020 Jul;43(7):648-654. doi: 10.1038/s41440-020-0455-8. Epub 2020 Apr 27.
10
Angiotensin Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use Among Outpatients Diagnosed With COVID-19.COVID-19 门诊患者中血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂的使用情况。
Am J Cardiol. 2020 Oct 1;132:150-157. doi: 10.1016/j.amjcard.2020.07.007. Epub 2020 Jul 12.

引用本文的文献

1
Real-world effectiveness and safety of oral azvudine versus Paxlovid in patients with COVID-19 and pre-existing hypertension: a multicentre, retrospective, cohort study in Henan Province, China.口服阿兹夫定与帕罗韦德治疗新型冠状病毒肺炎合并高血压患者的真实世界有效性和安全性：中国河南省一项多中心、回顾性队列研究
BMJ Open. 2025 Jun 27;15(6):e090230. doi: 10.1136/bmjopen-2024-090230.
2
The effect of coronavirus infection on QT and QTc intervals of hospitalized patients in Qazvin, Iran.冠状病毒感染对伊朗加兹温住院患者QT及QTc间期的影响。
Ann Data Sci. 2022 Aug 4:1-12. doi: 10.1007/s40745-022-00425-5.
3
Myocarditis and Inflammatory Cardiomyopathy in Dilated Heart Failure.

本文引用的文献

1
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）进入细胞依赖于 ACE2 和 TMPRSS2，可被一种临床验证的蛋白酶抑制剂所阻断。
Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.
2
Clinical Characteristics of Coronavirus Disease 2019 in China.《中国 2019 年冠状病毒病临床特征》
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
3
Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury.
扩张型心力衰竭中的心肌炎与炎症性心肌病
Viruses. 2025 Mar 27;17(4):484. doi: 10.3390/v17040484.
4
Computational Evidence for Bisartan Arginine Blockers as Next-Generation Pan-Antiviral Therapeutics Targeting SARS-CoV-2, Influenza, and Respiratory Syncytial Viruses.双沙坦精氨酸阻滞剂作为靶向严重急性呼吸综合征冠状病毒2（SARS-CoV-2）、流感病毒和呼吸道合胞病毒的下一代泛抗病毒疗法的计算证据
Viruses. 2024 Nov 14;16(11):1776. doi: 10.3390/v16111776.
5
COVID-19 related acute necrotizing encephalopathy and acute myocarditis in an adult female: a novel case report of brain injury and myocarditis.成人女性 COVID-19 相关急性坏死性脑病和急性心肌炎：脑损伤和心肌炎的新病例报告。
BMC Neurol. 2024 Aug 6;24(1):274. doi: 10.1186/s12883-024-03786-x.
6
Lisinopril increases lung ACE2 levels and SARS-CoV-2 viral load and decreases inflammation but not disease severity in experimental COVID-19.在实验性新冠肺炎中，赖诺普利可提高肺部血管紧张素转换酶2（ACE2）水平和严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒载量，并减轻炎症，但不会降低疾病严重程度。
Front Pharmacol. 2024 Jul 12;15:1414406. doi: 10.3389/fphar.2024.1414406. eCollection 2024.
7
Pathogenic mechanisms of cardiovascular damage in COVID-19.COVID-19 中心血管损伤的发病机制。
Mol Med. 2024 Jun 19;30(1):92. doi: 10.1186/s10020-024-00855-2.
8
Frontiers and hotspots evolution in cytokine storm: A bibliometric analysis from 2004 to 2022.细胞因子风暴的前沿与热点演变：2004年至2022年的文献计量分析
Heliyon. 2024 May 10;10(10):e30955. doi: 10.1016/j.heliyon.2024.e30955. eCollection 2024 May 30.
9
Assessment of cardiac adverse events following COVID-19 vaccination by speckle tracking echocardiography.基于斑点追踪超声心动图评估 COVID-19 疫苗接种后的心脏不良事件。
Sci Rep. 2024 May 13;14(1):10849. doi: 10.1038/s41598-024-61641-y.
10
Evaluation of blood pressure variation in recovered COVID-19 patients at one-year follow-up: a retrospective cohort study.恢复期 COVID-19 患者一年随访时血压变异性评估：一项回顾性队列研究。
BMC Cardiovasc Disord. 2024 May 7;24(1):240. doi: 10.1186/s12872-024-03916-w.
从 2019 年新冠病毒感染患者中提取的临床和生化指标与病毒载量和肺部损伤有关。
Sci China Life Sci. 2020 Mar;63(3):364-374. doi: 10.1007/s11427-020-1643-8. Epub 2020 Feb 9.
4
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.《武汉 2019 年新型冠状病毒感染的肺炎 138 例住院患者临床特征分析》
JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.
5
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.中国武汉 99 例 2019 年新型冠状病毒肺炎患者的流行病学和临床特征：描述性研究。
Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30.
6
Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia.新型冠状病毒感染肺炎在中国武汉的早期传播动力学。
N Engl J Med. 2020 Mar 26;382(13):1199-1207. doi: 10.1056/NEJMoa2001316. Epub 2020 Jan 29.
7
Age-dependent differences in pulmonary host responses in ARDS: a prospective observational cohort study.急性呼吸窘迫综合征中肺部宿主反应的年龄依赖性差异：一项前瞻性观察队列研究。
Ann Intensive Care. 2019 May 14;9(1):55. doi: 10.1186/s13613-019-0529-4.
8
The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7).肾素-血管紧张素系统的 ACE2/血管紧张素-(1-7)/MAS 轴：关注血管紧张素-(1-7)。
Physiol Rev. 2018 Jan 1;98(1):505-553. doi: 10.1152/physrev.00023.2016.
9
Recombinant human ACE2: acing out angiotensin II in ARDS therapy.重组人血管紧张素转换酶2：在急性呼吸窘迫综合征治疗中胜过血管紧张素II 。
Crit Care. 2017 Dec 13;21(1):305. doi: 10.1186/s13054-017-1882-z.
10
A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome.一项重组人血管紧张素转换酶 2 在急性呼吸窘迫综合征中的临床试验。
Crit Care. 2017 Sep 7;21(1):234. doi: 10.1186/s13054-017-1823-x.